ES2167312T3 - Profarmacos para antagonistas de la colecistoquinina. - Google Patents

Profarmacos para antagonistas de la colecistoquinina.

Info

Publication number
ES2167312T3
ES2167312T3 ES91918120T ES91918120T ES2167312T3 ES 2167312 T3 ES2167312 T3 ES 2167312T3 ES 91918120 T ES91918120 T ES 91918120T ES 91918120 T ES91918120 T ES 91918120T ES 2167312 T3 ES2167312 T3 ES 2167312T3
Authority
ES
Spain
Prior art keywords
agents
drugs
useful
treatment
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918120T
Other languages
English (en)
Inventor
David Christopher Horwell
Martyn Clive Pritchard
Reginald Stewart Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/726,653 external-priority patent/US5340825A/en
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2167312T3 publication Critical patent/ES2167312T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE PRESENTAN NUEVAS PRO-DROGAS PARA NUEVOS DIPEPTOIDES NO NATURALES DE DERIVADOS TRP-PHE SUSTITUIDOS EN (ALFA) UTILES COMO AGENTES EN EL TRATAMIENTO DE LA OBESIDAD, LA HIPERSECRECION DE ACIDO GASTRICO EN EL ESTOMAGO, LOS TUMORES DEPENDIENTES DE LAS GASTRINA O COMO ANTISICOTICOS. ADEMAS, LOS DIPEPTOIDES SON AGENTES ANSIOLITICOS Y AGENTES ANTIULCEROSOS. LOS PEPTOIDES SON AGENTES UTILES PARA PREVENIR LA RESPUESTA A LA SUSPENSION DE TRATAMIENTOS CRONICOS O CON EL USO DE LA NICOTINA, EL DIAPEZAM, EL ALCOHOL, LA COCAINA, LA CAFEINA O LOS OPIACEOS. LAS PRO-DROGAS SON TAMBIEN UTILES EN EL TRATAMIENTO Y/O PREVENCION DE ATAQUES DE PANICO. TAMBIEN SE PRESENTAN COMPOSICIONES FARMACEUTICAS Y METODOS DE TRATAMIENTO QUE USAN LAS PRO-DROGAS ASI COMO PROCESOS PARA SU PREPARACION Y NUEVOS PRODUCTOS INTERMEDIOS UTILES EN SU PREPARACION. ADEMAS, UNA CARACTERISTICA ADICIONAL DE LA INVENCION ES EL USO DE LOS COMPUESTOS DE PRO-DROGAS EN COMPOSICIONES PARA DIAGNOSTICO.
ES91918120T 1990-08-31 1991-08-29 Profarmacos para antagonistas de la colecistoquinina. Expired - Lifetime ES2167312T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57631590A 1990-08-31 1990-08-31
US07/726,653 US5340825A (en) 1990-08-31 1991-07-12 Pro drugs for CCK antagonists

Publications (1)

Publication Number Publication Date
ES2167312T3 true ES2167312T3 (es) 2002-05-16

Family

ID=27076930

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918120T Expired - Lifetime ES2167312T3 (es) 1990-08-31 1991-08-29 Profarmacos para antagonistas de la colecistoquinina.

Country Status (14)

Country Link
US (2) US5554643A (es)
EP (1) EP0546108B1 (es)
JP (1) JP3356431B2 (es)
AT (1) ATE208400T1 (es)
AU (1) AU649077B2 (es)
CA (1) CA2088980C (es)
DE (1) DE69132805T2 (es)
DK (1) DK0546108T3 (es)
ES (1) ES2167312T3 (es)
IE (1) IE913079A1 (es)
NO (1) NO300324B1 (es)
NZ (1) NZ239591A (es)
PT (1) PT98831B (es)
WO (1) WO1992004038A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2167312T3 (es) * 1990-08-31 2002-05-16 Warner Lambert Co Profarmacos para antagonistas de la colecistoquinina.
AU665562B2 (en) * 1991-07-12 1996-01-11 Warner-Lambert Company Cholecystokinin antagonists useful in the treatment of panic attacks
US5217957A (en) * 1991-08-20 1993-06-08 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
US5380872A (en) * 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
NZ255721A (en) * 1992-08-13 1997-06-24 Warner Lambert Co Hetarylmethoxy carbonyl substituted tryptophan amides, esters, analogues and pharmaceutical compositions thereof
TW281669B (es) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US6869957B1 (en) 1993-11-17 2005-03-22 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US6129685A (en) * 1994-02-09 2000-10-10 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US7077822B1 (en) 1994-02-09 2006-07-18 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
CA2152765A1 (en) 1994-06-30 1995-12-31 Jeroen Elisabeth-Joseph Knops Methods for treating a physiological disorder associated with beta amyloid peptide
US7109326B2 (en) * 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
US8278355B2 (en) 2006-09-12 2012-10-02 Therexcell Pharma Inc. Isovaline for treatment of pain
WO2017158621A1 (en) * 2016-03-14 2017-09-21 Sphaera Pharma Pvt. Ltd. Trigonelline based compounds
WO2020070557A1 (en) * 2018-10-02 2020-04-09 Q Biomed Inc. Modified therapeutic agent analogs of mefenamic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2364659A1 (fr) * 1976-09-21 1978-04-14 Commissariat Energie Atomique Medicament antagoniste de l'action de la gastrine et des polypeptides apparentes
US4757151A (en) * 1985-11-14 1988-07-12 Warner-Lambert Company 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5278316A (en) * 1989-06-29 1994-01-11 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives
NZ234264A (en) * 1989-06-29 1993-05-26 Warner Lambert Co N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions
ES2167312T3 (es) * 1990-08-31 2002-05-16 Warner Lambert Co Profarmacos para antagonistas de la colecistoquinina.

Also Published As

Publication number Publication date
DE69132805T2 (de) 2002-10-24
NO930710D0 (no) 1993-02-26
NZ239591A (en) 1994-07-26
JP3356431B2 (ja) 2002-12-16
PT98831A (pt) 1992-08-31
PT98831B (pt) 1999-02-26
JPH06501007A (ja) 1994-01-27
ATE208400T1 (de) 2001-11-15
US5726200A (en) 1998-03-10
CA2088980C (en) 2002-04-16
EP0546108A1 (en) 1993-06-16
IE913079A1 (en) 1992-03-11
NO930710L (no) 1993-04-21
EP0546108B1 (en) 2001-11-07
WO1992004038A1 (en) 1992-03-19
NO300324B1 (no) 1997-05-12
CA2088980A1 (en) 1992-03-01
EP0546108A4 (en) 1993-09-22
DE69132805D1 (de) 2001-12-13
US5554643A (en) 1996-09-10
DK0546108T3 (da) 2002-02-18
AU8725091A (en) 1992-03-30
AU649077B2 (en) 1994-05-12

Similar Documents

Publication Publication Date Title
ES2167312T3 (es) Profarmacos para antagonistas de la colecistoquinina.
Willow et al. The effects of swimming in mice on pain perception and sleeping time in response to hypnotic drugs
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
AR035792A1 (es) Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NO915122L (no) N-substituerte cykloalkyl- og polycykloalkyl- alfa-substituerte trp-phe- og fenetylamin-derivater
DK160129C (da) Farmaceutisk praeparat indeholdende en gangliosidforbindelse, et indre ester-gangliosidderivat eller blandinger deraf
ES2070131T3 (es) Sistemas farmaco-lipido de baja toxicidad.
ES2039408T3 (es) Un procedimiento para preparar un compuesto de tienotriazolodiazepina.
SE8704952D0 (sv) Farmaceutisk komposition
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
FR2763592B1 (fr) Nouveaux derives glycosyles des ginkgolides, leur application en tant que medicaments et compositions pharmaceutiques les contenant
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
FR2599036B1 (fr) Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
AR023139A1 (es) Nuevos derivados de morfolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PT91051A (pt) Processo para a preparacao de novos derivados de glicerina e de composicoes farmaceuticas que os contem
ES2036545T3 (es) Derivados de n-1h-tetrazol-5-il-(anillo de 5 eslabones)-carboxamida, un procedimiento para su preparacion y el uso de los mismos.
ES2152564T3 (es) Procedimientos e intermedios para preparar 3-(1-piperazinil)-1,2-benzoisotiazol.
NO905327L (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbamoylderivater.
ES2061531T3 (es) Derivados de azepinona y azocinona condensados, procedimientos para su preparacion, agentes que los contienen y su utilizacion, asi como productos intermedios en su preparacion.
IT1204764B (it) Utilizzazione terapeutica del fruttosio-1,6-difosfato per la protezione nei confronti della tossicita' indotta da somministrazione di antitumorali antraciclinici
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina